Rebuttal From Dr Pavord

[摘要] I find myself agreeing with almost all of Professor Chalmer’s comments.¹ I accept that this is not in the spirit of a pro-con debate, but suggest it represents a much more important and exciting development: an emerging consensus on the use of inhaled corticosteroids (ICS) in patients with COPD. We both recommend that treatment be initiated in patients who have evidence of involvement of the relevant biologic pathway rather than in those who possess an arbitrary label. We agree that in the blood eosinophil count we have a convenient and reasonably robust biomarker of corticosteroid-responsive eosinophilic airway inflammation.

[学科分类] 呼吸医学